| Autor: |
Bates TA; Department of Molecular Microbiology and Immunology., Leier HC; Department of Molecular Microbiology and Immunology., McBride SK; Department of Molecular Microbiology and Immunology., Schoen D; Division of Infectious Diseases, and., Lyski ZL; Department of Molecular Microbiology and Immunology., Lee DX; Department of Molecular Microbiology and Immunology., Messer WB; Department of Molecular Microbiology and Immunology.; Division of Infectious Diseases, and.; OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, Oregon, USA., Curlin ME; Division of Infectious Diseases, and., Tafesse FG; Department of Molecular Microbiology and Immunology. |
| Jazyk: |
angličtina |
| Zdroj: |
JCI insight [JCI Insight] 2023 Mar 08; Vol. 8 (5). Date of Electronic Publication: 2023 Mar 08. |
| DOI: |
10.1172/jci.insight.165265 |
| Abstrakt: |
As the COVID-19 pandemic continues, long-term immunity against SARS-CoV-2 will be important globally. Official weekly cases have not dropped below 2 million since September of 2020, and continued emergence of novel variants has created a moving target for our immune systems and public health alike. The temporal aspects of COVID-19 immunity, particularly from repeated vaccination and infection, are less well understood than short-term vaccine efficacy. In this study, we explored the effect of combined vaccination and infection, also known as hybrid immunity, and the timing thereof on the quality and quantity of antibodies elicited in a cohort of 96 health care workers. We found robust neutralizing antibody responses among those with hybrid immunity; these hybrid immune responses neutralized all variants, including BA.2. Neutralizing titers were significantly improved for those with longer vaccine-infection intervals of up to 400 days compared with those with shorter intervals. These results indicate that anti-SARS-CoV-2 antibody responses undergo continual maturation following primary exposure by either vaccination or infection for at least 400 days after last antigen exposure. We show that neutralizing antibody responses improved upon secondary boosting, with greater potency seen after extended intervals. Our findings may also extend to booster vaccine doses, a critical consideration in future vaccine campaign strategies. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
